Aeon's $14M Seed Round and Acquisition: A New Era for European Health Tech?

Jan de Vries · 2026-09-14

Zurich-based Aeon just made a bold move that could change how we think about preventive healthcare. The company closed a Seed extension, bringing its total funding to over $14 million, and acquired German blood diagnostics platform Aware Health. This isn't just another funding round—it's a statement that the future of health is proactive, not reactive. ### The Deal That Accelerates Everything Aeon's journey began in 2023 with a simple but powerful idea: combine whole-body MRI with recurring blood diagnostics, then let AI connect the dots. Their platform already detects over 500 anomalies and analyzes more than 100 biomarkers. But the acquisition of Aware Health? That's the game-changer. Aware Health brings a fully regulated diagnostics stack, live lab integrations, and a network of over 45 blood-draw locations. They've served nearly 10,000 active customers. By folding this into Aeon, the company says it's two years ahead of schedule. > "Imaging tells you where you are. Blood diagnostics tell you where you're heading. AI is what connects the two into prediction," says Tim Seithe, founder and CEO of Aeon. "The acquisition of Aware Health accelerates that vision by two years, and this round gives us everything we need to execute." ### Why This Matters for Preventive Care Most health check-ups are snapshots—a single moment in time. Aeon wants to turn that into a movie. By combining episodic imaging with recurring blood tests, they're building a continuous, longitudinal health record for each customer. That means AI can spot trends, flag deviations early, and predict risks before they become disease. And it's working: over 90% of Aeon check-ups surface actionable findings, with a significant finding rate of 15.4%. That's not just data—it's lives potentially saved. ### The Investors Betting on This Vision The round was co-led by Araya Ventures, with existing investors like Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital, and Bigwave Capital all participating. Rupa Popat, Founding and Managing Partner at Araya Ventures, explains: "Aeon is building something genuinely new in European healthcare. The combination of imaging, recurring blood diagnostics, and AI creates a longitudinal health picture that no other platform in Europe offers." ### A Growing Trend in European Health Tech Aeon isn't alone. Other startups are racing to redefine preventive care. Zurich-based Ahead Health raised over $15 million this year, and Paris-based Lucis secured $18 million for its AI-supported blood biomarker platform. Even Neko Health's massive Series C—over $660 million—shows investors are hungry for this space. But Aeon's acquisition of Aware Health sets it apart. It's the first European platform to offer a truly continuous health picture, updated quarter after quarter. As Seithe puts it, "We're redefining preventive care by shifting it from reaction to action." ### What's Next? With the Berlin team now under Aeon's wing, the company is poised to scale. They're not just selling check-ups; they're selling peace of mind. And in a world where healthcare is often reactive, that's a powerful proposition. For anyone watching the European startup scene, Aeon is a name to remember. They're not just raising money—they're raising the bar.